New treatments are needed for the management of active lupus. Epratuzumab a humanized IgG1 monoclonal antibody that targets CD22 resulting in selective B cell modulation that has been considered a potential treatment for SLE.

2007年10月21日 · Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22.

Epratuzumab is a humanized monoclonal antibody, which can rapidly induce a marked decrease of CD22 (>80%) and slight inhibition of other proteins from the B-cell surface in vitro, including CD19, CD21 and CD79β (15, 16). Initially, epratuzumab was used as a promising immunotherapy for non-Hodgkin's lymphoma (13).

2014年11月17日 · Epratuzumab is a humanized anti-CD22 monoclonal antibody that targets CD22 on B-cell and its role in B-cell modulation, migration, function, and inhibition of B-cell receptor signaling. Epratuzumab is currently in a Phase III study evaluating its efficacy in the management of moderate to severe SLE.

Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of B cells. The aim of this study was to report the results of 2 phase III multicenter randomized, double‐blind, ...

2017年1月28日 · In the present report, we present the results of the 2 phase III multicenter, randomized, placebo‐controlled, double‐blind EMBODY 1 and EMBODY 2 trials, which aimed to demonstrate the efficacy and safety of epratuzumab in the treatment of patients with moderately to severely active SLE.

Treatment with epratuzumab 2400 mg cd was well tolerated in patients with moderately to severely active SLE, and associated with improvements in disease activity. Phase III studies are ongoing.

2003年9月1日 · Purpose: Epratuzumab is a novel humanized antihuman CD22 IgG1 antibody that has recently shown promising clinical activity, both as a single agent and in combination with rituximab, in patients with non-Hodgkin’s lymphomas (NHL).

Epratuzumab (anti-CD22 mAb targeting B cells) provides clinically meaningful reductions in corticosteroids (CS) use with a favourable safety profile in patients with moderate/severe flaring SLE: results from randomised controlled trials (RCTs).

2003年9月1日 · Purpose: Epratuzumab is a novel humanized antihuman CD22 IgG1 antibody that has recently shown promising clinical activity, both as a single agent and in combination with rituximab, in patients with non-Hodgkin's lymphomas (NHL).